213201-98-0

Basic information

• Product Name: 2,4-DICHLORO-6-PIPERIDINYLPYRIMIDINE
• Synonyms: 2,4-DICHLORO-6-PIPERIDINYLPYRIMIDINE;2,4-dichloro-6-(piperidin-1-yl)pyriMidine;2,4-Dichloro-6-(1-piperidinyl)pyrimidine
• CAS NO: 213201-98-0
• Molecular Formula: C₉H₁₁Cl₂N₃
• Molecular Weight: 232.11
• Mol File: 213201-98-0.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 372.1±27.0 °C(Predicted)
• Appearance: /
• Density: 1.349
• PKA: 0.59±0.39(Predicted)
• CAS DataBase Reference: 2,4-DICHLORO-6-PIPERIDINYLPYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-DICHLORO-6-PIPERIDINYLPYRIMIDINE(213201-98-0)
• EPA Substance Registry System: 2,4-DICHLORO-6-PIPERIDINYLPYRIMIDINE(213201-98-0)

Safety Data

• Hazardous Substances Data: 213201-98-0(Hazardous Substances Data)

Usage

General Description

2,4-Dichloro-6-piperidinylpyrimidine is a chemical compound with the molecular formula C9H9Cl2N3. It is a pyrimidine-based herbicide that is used to control a wide range of broadleaf weeds in crops, lawns, and other vegetation. It works by inhibiting the enzyme acetohydroxyacid synthase, which is necessary for the biosynthesis of the branched-chain amino acids isoleucine, leucine, and valine. This disruption in amino acid synthesis ultimately leads to the death of the targeted weeds. 2,4-Dichloro-6-piperidinylpyrimidine is an effective and widely used herbicide that plays an important role in agriculture and weed control.

Upstream product

• 110-89-4 piperidine 
• 3764-01-0 2,4,6-trichloropyrimidine 

Downstream Products

• 1350641-32-5 C₂₂H₂₃ClFN₅O 
• 1350641-31-4 N₄-(3-fluoro-2-methylphenyl)-N₂-(4-methoxyphenyl)-6-(piperidin-1-yl)pyrimidine-2,4-diamine 
• 1350641-30-3 C₂₃H₂₆FN₅O 
• 1350641-29-0 C₂₄H₂₆F₃N₅O 
• 1350641-28-9 N₄-(3-fluoro-4-methoxyphenyl)-N₂-(4-methoxyphenyl)-6-(piperidin-1-yl)pyrimidine-2,4-diamine 
• 1350641-27-8 C₂₃H₂₅F₂N₅O₂ 
• 1350641-26-7 N₄-(3-(difluoromethoxy)phenyl)-N₂-(4-methoxyphenyl)-6-(piperidin-1-yl)pyrim-idine-2,4-diamine 
• 1350641-25-6 C₂₃H₂₄F₃N₅O 
• 1350641-24-5 N₂-(4-methoxyphenyl)-6-(piperidin-1-yl)-N₄-(4-(trifluoromethoxy)phene-yl)pyrimidine-2,4-diamine 
• 1350641-23-4 N₂-(4-methoxyphenyl)-6-(piperidin-1-yl)-N₄-(3-(trifluoromethoxy)phenyl)pyrimidine-2,4-diamine 
• 1350641-22-3 C₂₄H₂₉N₅O 
• 1350641-21-2 C₂₄H₂₉N₅O 
• 1350641-20-1 C₂₇H₃₁F₄N₇ 
• 1350641-19-8 C₂₇H₃₁F₄N₇O 

Relevant articles and documents

Novel antiallergic agents. Part I: Synthesis and pharmacology of pyrimidine amide derivatives

We have synthesized many pyrimidine amide derivatives. Novel pyrimidine bis-glycolic amide derivatives showed moderate inhibition in the rat passive cutaneous anaphylaxis (PCA) assay by oral administration. Among these compounds, 2,4-bis(methoxyacetylamino)-6-piperidinopyrirnidine (2i) exhibited significant inhibition. However the compound (2i) did not inhibit antigen-induced histamine or SRS-A release from lung fragments of the guinea-pig at less than 10-4 M. Derivatives of 2i have also notable or moderate activity in the rat PCA assay. Compound 2h which has no oxygen atom at the α-position of the amide carbonyl group and, compound 17 which has no amide carbonyl group, showed no inhibition in the rat PCA assay. We supposed that both the amide carbonyl group and the oxygen atom at α-position of the amide carbonyl group play an important role in inhibiting the rat PCA reaction. These pyrimidine bis-glycolic amide derivatives have a novel structure and unique activity which suggests they may be potentially useful in the treatment of allergic diseases. Copyright (C) 1998 Elsevier Science Ltd.

HEPATITIS B VIRAL ASSEMBLY EFFECTORS

Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.